Aclarion (NASDAQ:ACON – Get Free Report) and Beauty Health (NASDAQ:SKIN – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.
Institutional and Insider Ownership
7.5% of Aclarion shares are held by institutional investors. Comparatively, 93.3% of Beauty Health shares are held by institutional investors. 0.8% of Aclarion shares are held by company insiders. Comparatively, 41.0% of Beauty Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Aclarion and Beauty Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aclarion | -10,908.50% | -71.11% | -65.96% |
| Beauty Health | -3.87% | -19.70% | -1.97% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aclarion | 1 | 1 | 0 | 0 | 1.50 |
| Beauty Health | 1 | 4 | 1 | 1 | 2.29 |
Aclarion presently has a consensus target price of $11,758.50, indicating a potential upside of 187,435.89%. Beauty Health has a consensus target price of $2.81, indicating a potential upside of 116.35%. Given Aclarion’s higher possible upside, equities research analysts plainly believe Aclarion is more favorable than Beauty Health.
Earnings and Valuation
This table compares Aclarion and Beauty Health”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aclarion | $62,948.00 | 57.97 | -$6.99 million | ($1,363.42) | 0.00 |
| Beauty Health | $301.92 million | 0.55 | -$29.10 million | ($0.22) | -5.91 |
Aclarion has higher earnings, but lower revenue than Beauty Health. Beauty Health is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Aclarion has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Beauty Health has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
Summary
Beauty Health beats Aclarion on 10 of the 15 factors compared between the two stocks.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
